



2025 TASLC International Symposium on Treatment Advances in Lung Cancer



線上報名

01/11 (Sat.) 08:20-17:50

Time		Topic	Presenter/Discussant	Chair/Moderator
Satellite Symposium				
08:20-09:00	MSD	Real-world first-line application from Europe of advanced wild-type adenocarcinoma regardless of PD-L1 expression	Martin Reck	Inn-Wen Chong
Plenary Lecture				
09:00-09:10		Opening Address	James CH Yang	
09:10-09:30		First-line treatment for Stage IV <i>EGFR</i> -mutated NSCLC	Pasi Jänne	James CH Yang
09:30-09:45		Case presentation	Hsin-Yi Wang	Jin-Yuan Shih
09:45-10:30		Optimal frontline treatment for advanced <i>EGFR</i> -mutated NSCLC	Pasi Jänne Daniel Tan Hidetoshi Hayashi Jessica Lin Jin-Yuan Shih	James CH Yang
Coffee Break				
11:00-11:15		Case presentation	Chiao-En Wu	Wen-Cheng Chang
11:15-12:00		Treatment after failure of first-line <i>EGFR</i> TKI for <i>EGFR</i> -mutated stage IV NSCLC	Daniel Tan Jessica Lin Myung-Ju Ahn Hidehito Horinouchi Shang-Gin Wu	Tony Mok
Satellite Symposium				
12:00-12:40	AstraZeneca	Redefining standards in NSCLC therapy: the case for prioritizing third-generation <i>EGFR</i> -TKIs	Pasi Jänne	Chao-Hua Chiu
12:40-13:20	Pfizer	Optimizing <i>ALK</i> -positive metastatic NSCLC patient care – from RCT to real-world practice	Benjamin Solomon	Chong-Jen Yu
Lunch Break				
Plenary Lecture				
13:40-14:00		Looking forward to treatment of stage IV NSCLC without driver mutations: novel immunotherapies	Solange Peters	Inn-Wen Chong
14:00-14:15		Case presentation	Ching-Yao Yang	Chien-Chung Lin
14:15-15:00		Beyond PD1/PDL1 inhibition	Justin Gainor Benjamin Solomon Martin Reck Myung-Ju Ahn Chien-Chung Lin	Alex Adjei
Coffee Break				
15:30-15:50		Antibody-drug conjugates: current status and future prospective	Myung-Ju Ahn	Chia-Chi Lin
15:50-16:05		Case presentation	Wei-Hsun Hsu	Tsung-Ying Yang
16:05-16:50		Antibody-drug conjugates: monotherapy or combination therapy?	Karen Kelly Hidehito Horinouchi Pasi Jänne Hidetoshi Hayashi Tsung-Ying Yang	Heather Wakelee
16:50-17:10	Special Lecture	Immune microenvironment	Justin Gainor	Chong-Jen Yu
Satellite Symposium				
17:10-17:50	Chugai	Treatment strategy on the whole journey of <i>ALK</i> -positive NSCLC: from early to late stages	Hidehito Horinouchi	James CH Yang
Gala Dinner				
18:00-21:00				



台灣肺癌研究學會
Taiwan Association for the Study of Lung Cancer

2025 TASLC International Symposium on Treatment Advances in Lung Cancer



線上報名

01/12 (Sun.) 08:20-15:10

Time		Topic	Presenter/Discussant	Chair/Moderator
Satellite Symposium				
08:20-09:00	Johnson & Johnson	Clinical experience and perspectives from Singapore on the use of amivantamab in common <i>EGFR</i> -mutated NSCLC	Daniel Tan	Tsung-Ying Yang
Plenary Lecture				
09:00-09:10	Opening of 2nd day		Gee-Chen Chang	
09:10-09:30	IASLC lung cancer staging update and future perspective		Young Tae Kim	Pan-Chyr Yang
09:30-09:45	Case presentation		Pei-Hsing Chen	Jin-Shing Chen
09:45-10:30	Is the current staging system sufficient for clinicians to select the best treatment?		David Gandara Tony Mok Fred Hirsch Gee-Chen Chang	Tetsuya Mitsudomi
Coffee Break				
11:00-11:20	Treatment of stage I-III NSCLC		Heather Wakelee	Chao-Chi Ho
11:20-11:35	Case presentation		Chi-Lu Chiang	Chao-Hua Chiu
11:35-12:20	Neoadjuvant and adjuvant treatment		Karen Kelly Tetsuya Mitsudomi Young Tae Kim Chao-Hua Chiu	Martin Reck
Satellite Symposium				
12:20-13:00	Roche	First-line immunotherapy in advanced NSCLC management	Mokoto Nishio	Chao-Chi Ho
Lunch Break				
Plenary Lecture				
13:30-13:50	Stage III/IV NSCLC looking forward to long term control		James CH Yang	
13:50-14:05	Case presentation		Derek De-Rui Huang	James CH Yang
14:05-15:00	Treatment of stage III/IV NSCLC patients aiming for cure		Solange Peters Fred Hirsch Karen Kelly David Gandara	James CH Yang
15:00-15:10	Concluding Remarks		James CH Yang	

Jan.11 Sat ~12 Sun 2025

臺大醫院癌醫中心分院
國際會議中心

National Taiwan University Cancer Center
International Conference Center

